Annals of Hepato-Biliary-Pancreatic Surgery (한국간담췌외과학회지)

The Korean Association of Hepato-Biliary-Pancreatic Surgery (한국간담췌외과학회)
권호 표지

Predictive factors for invasive intraductal papillary mucinous neoplasm of the pancreas

  • Jun, Dae-Young (Department of Surgery, Kyungpook National University School of Medicine) ;
  • Kwon, Hyung-Jun (Department of Surgery, Kyungpook National University Medical Center) ;
  • Kim, Sang-Geol (Department of Surgery, Kyungpook National University Medical Center) ;
  • Kim, Sung-Hi (Department of Family Medicine, Daegu Catholic University College of Medicine) ;
  • Chun, Jae-Min (Department of Surgery, Kyungpook National University School of Medicine) ;
  • Kwon, Young-Bong (Department of Surgery, Kyungpook National University School of Medicine) ;
  • Yoon, Kyung-Jin (Department of Surgery, Kyungpook National University Medical Center) ;
  • Hwang, Yoon-Jin (Department of Surgery, Kyungpook National University Medical Center) ;
  • Yun, Young-Kook (Department of Surgery, Kyungpook National University School of Medicine)
  • Published : 2011.11.30
⟨ Previous Next ⟩

Abstract

Backgrounds/Aims: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has malignant potential. Predicting invasive IPMN has proven difficult and controversial. We tried to identify predictive factors for invasive IPMN. Methods: Thirty six patients underwent resection for IPMN from February 2001 to July 2011. Clinicopathological features including demographic, imaging, microscopic, and serological findings were retrospectively reviewed. Receiver operating characteristic (ROC) curve analysis was used to analyze sensitivity and specificity of all possible cut-off values for the diameter of the main pancreatic duct and mass size predicting invasive IPMN. Student t-test, chi-square test, and logistic regression were used for univariate and multivariate analysis. Results: The mean age was $63.5{\pm}8.4$ years. Males were more commonly affected (58.3% vs 41.7%). Pancreaticoduodenectomy was performed in 55.6% of patients, distal pancreatectomy in 36.1%, and central pancreatic resection in 8.3%. Non-invasive IPMNs were present in 80.6% (n=29), whereas invasive IPMNs were present in 19.4% (n=7). In univariate analysis, tumor location (p=0.036), Kuroda classification (p=0.048), mural nodule (p=0.016), and main duct dilatation ${\geq}8mm$) (p=0.006) were statistically significant variables. ROC curve analysis showed that a value of 8 mm for the main duct dilatation and a value of 35 mm for the size of the mass lesion have 80% sensitivity and 75% specificity and 100% sensitivity and 82.6% specificity, respectively. However, in multivariate analysis, main ductal dilatation (${\geq}8mm$) was identified to be the only independent factor for invasive IPMN (p=0.049). Conclusions: Main duct dilatation appears to be a useful indicator for predicting invasive IPMN.

Keywords

References

  1. Kloppel G, Solcia E, Longnecker DS, et al. World Health Organization International Histological Classification of Tumours: Histological Typing of Tumors of the Exocrine Pancreas. 2nd ed. Berlin; Springer-Verlag, 1996.
  2. Cho KR, Vogelstein B. Genetic alterations in the adenoma--carcinoma sequence. Cancer 1992;70(6 Suppl):1727-1731. https://doi.org/10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P
  3. Wilentz RE, Hruban RH. Pathology of cancer of the pancreas. Surg Oncol Clin N Am 1998;7:43-65.
  4. Taouli B, Vilgrain V, O'Toole D, Vullierme MP, Terris B, Menu Y. Intraductal papillary mucinous tumors of the pancreas: features with multimodality imaging. J Comput Assist Tomogr 2002;26:223-231. https://doi.org/10.1097/00004728-200203000-00011
  5. Sohn TA, Yeo CJ, Cameron JL, et al. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788-797. https://doi.org/10.1097/01.sla.0000128306.90650.aa
  6. Klimstra DS. Cystic, mucin-producing neoplasms of the pancreas: the distinguishing features of mucinous cystic neoplasms and intraductal papillary mucinous neoplasms. Semin Diagn Pathol 2005;22:318-329. https://doi.org/10.1053/j.semdp.2006.04.005
  7. Bosman FT, Carneiro F, Hruban RH, et al. WHO Classification of Tumours of the Digestive System: Tumours of the Pancreas. 4th ed. Berlin; Springer, 2010.
  8. Baba T, Yamaguchi T, Ishihara T, et al. Distinguishing benign from malignant intraductal papillary mucinous tumors of the pancreas by imaging techniques. Pancreas 2004;29:212-217. https://doi.org/10.1097/00006676-200410000-00006
  9. Chiu SS, Lim JH, Lee WJ, et al. Intraductal papillary mucinous tumour of the pancreas: differentiation of malignancy and benignancy by CT. Clin Radiol 2006;61:776-783. https://doi.org/10.1016/j.crad.2006.04.008
  10. Sahani DV, Kadavigere R, Blake M, et al. Intraductal papillary mucinous neoplasm of pancreas: multi-detector row CT with 2D curved reformations--correlation with MRCP. Radiology 2006;238:560-569. https://doi.org/10.1148/radiol.2382041463
  11. Ogawa H, Itoh S, Ikeda M, Suzuki K, Naganawa S. Intraductal papillary mucinous neoplasm of the pancreas: assessment of the likelihood of invasiveness with multisection CT. Radiology 2008;248:876-886. https://doi.org/10.1148/radiol.2482071578
  12. Jang JY, Kim SW, Ahn YJ, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: is it possible to predict the malignancy before surgery? Ann Surg Oncol 2005;12:124-132. https://doi.org/10.1245/ASO.2005.02.030
  13. Tanaka M, Chari S, Adsay V, et al; International Association of Pancreatology. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32. https://doi.org/10.1159/000090023
  14. Pelaez-Luna M, Chari ST, Smyrk TC, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol 2007;102:1759-1764. https://doi.org/10.1111/j.1572-0241.2007.01224.x
  15. Kobayashi G, Fujita N, Noda Y, et al. Mode of progression of intraductal papillary-mucinous tumor of the pancreas: analysis of patients with follow-up by EUS. J Gastroenterol 2005;40:744-751. https://doi.org/10.1007/s00535-005-1619-7
  16. Yamaguchi T, Baba T, Ishihara T, et al. Long-term follow-up of intraductal papillary mucinous neoplasm of the pancreas with ultrasonography. Clin Gastroenterol Hepatol 2005;3:1136-1143. https://doi.org/10.1016/S1542-3565(05)00756-1
  17. Schmidt CM, White PB, Waters JA, et al. Intraductal papillary mucinous neoplasms: predictors of malignant and invasive pathology. Ann Surg 2007;246:644-651. https://doi.org/10.1097/SLA.0b013e318155a9e5
  18. Lee CJ, Scheiman J, Anderson MA, et al. Risk of malignancy in resected cystic tumors of the pancreas < or =3 cm in size: is it safe to observe asymptomatic patients? A multi-institutional report. J Gastrointest Surg 2008;12:234-242. https://doi.org/10.1007/s11605-007-0381-y
  19. Bassi C, Crippa S, Salvia R. Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife? Gut 2008;57:287-289. https://doi.org/10.1136/gut.2007.135392
  20. Vullierme MP, Giraud-Cohen M, Hammel P, et al. Malignant intraductal papillary mucinous neoplasm of the pancreas: in situ versus invasive carcinoma surgical resectability. Radiology 2007;245:483-490. https://doi.org/10.1148/radiol.2451060951
  21. Yamada Y, Mori H, Matsumoto S, Kamei N, Hongo N. Invasive carcinomas derived from intraductal papillary mucinous neoplasms of the pancreas: a long-term follow-up assessment with CT imaging. J Comput Assist Tomogr 2006;30:885-890. https://doi.org/10.1097/01.rct.0000220801.76276.0f
  22. Cho JH, Park SJ, Lee SM, et al. Surgical treatment of intraductal papillary mucinous tumor of the pancreas. Korean J HBP Surg 2007;11:36-41.